摘要
目的探讨利培酮联合小剂量碳酸锂治疗老年慢性精神分裂症的效果及对患者血清脑源性神经营养因子(BDNF)、星形胶质源性蛋白(S100B)及胶质纤维酸性蛋白(GFAP)水平的影响。方法选取2020年6月至2021年6月我院收治的50例老年慢性精神分裂症患者作为研究对象,将其随机分为对照组(25例,利培酮治疗)与观察组(25例,利培酮联合小剂量碳酸锂治疗)。比较两组患者的临床效果。结果观察组的治疗总有效率高于对照组(P<0.05)。治疗后,两组的5-HT、DA及NE水平均升高,且观察组高于对照组(P<0.05)。治疗后,两组的SAS、SDS评分均降低,且观察组低于对照组(P<0.05)。治疗后,两组的BPRS评分降低,HDS评分升高,且观察组优于对照组(P<0.05)。治疗后,两组的SSSI、IPROS评分均降低,且观察组低于对照组(P<0.05)。治疗后,两组的血清BDNF水平升高,S100B及GFAP水平降低,且观察组优于对照组(P<0.05)。两组的药物不良反应总发生率比较,差异无统计学意义(P>0.05)。治疗后,两组的WHOQOL-BREF各项评分升高,且观察组高于对照组(P<0.05)。结论利培酮联合小剂量碳酸锂治疗老年慢性精神分裂症患者的效果显著,可改善患者的神经递质水平及血清BDNF、S100B、GFAP水平,缓解焦虑、抑郁情绪,提升患者的精神状态、认知功能、社会功能、康复效果及生活质量,值得临床推广应用。
Objective To investigate the effect of risperidone combined with low-dose lithium carbonate in the treatment of senile chronic schizophrenia and its influences on serum brain-derived neurotrophic factor(BDNF),astrocyte-derived protein(S100 B) and glial fibrillary acidic protein(GFAP) levels of patients.Methods A total of 50 elderly patients with chronic schizophrenia treated in our hospital from June 2020 to June 2021 were selected as the research objects.The patients were randomly divided into control group(25 cases,treated with risperidone) and observation group(25 cases,treated with risperidone combined with low-dose lithium carbonate).The clinical effects of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,the levels of 5-HT,DA and NE in the two groups increased,and those in the observation group were higher than the control group(P<0.05).After treatment,the SAS and SDS scores in the two groups decreased,and those in the observation group were lower than the control group(P<0.05).After treatment,BPRS score decreased and HDS score increased in the two groups,and those in the observation group were better than the control group(P <0.05).After treatment,the scores of SSSI and IPROS in the two groups decreased,and those in the observation group were lower than the control group(P<0.05).After treatment,the serum BDNF level increased and the S100 B and GFAP levels decreased in the two groups,and those in the observation group were better than the control group(P <0.05).There was no significant difference in the total incidence of adverse drug reactions between the two groups(P >0.05).After treatment,the scores of WHOQOL-BREF in the two groups increased,and those in the observation group were higher than the control group(P<0.05).Conclusion Risperidone combined with low-dose lithium carbonate in the treatment of elderly patients with chronic schizophrenia has a significant effect,it can improve the levels of neurotransmitters and serum BDNF,S100 B and GFAP,alleviate anxiety and depression,and improve the mental state,cognitive function,social function,rehabilitation effect and quality of life of patients,which is worthy of clinical promotion and application.
作者
孙敦保
田佳荣
SUN Dunbao;TIAN Jiarong(Ankang Central Hospital,Ankang 725000,China)
出处
《临床医学研究与实践》
2022年第6期51-54,88,共5页
Clinical Research and Practice
作者简介
孙敦保(1967-),男,汉族,陕西旬阳人,副主任医师。研究方向:抑郁焦虑障碍、睡眠障碍、重性精神病障碍;通讯作者:田佳荣,E-mail:554669395@qq.com.
